Announcements Trials
Browse Landscape

Phase

Phase 1 23Phase NA 3Phase 1/2 3Phase 3 2Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 102CNS 5Gynecologic 2Genitourinary 2Thoracic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2267Lung Neoplasms 1050Small Cell Lung Carcinoma 403Adenocarcinoma of Lung 155Mesothelioma, Malignant 120Breast Neoplasms 110Neoplasms 106Brain Neoplasms 101Neoplasm Metastasis 95Melanoma 72Mesothelioma 70NSCLC 69Colorectal Neoplasms 69Adenocarcinoma, Bronchiolo-Alveolar 56Thymoma 53Pancreatic Neoplasms 52Head and Neck Neoplasms 47Ovarian Neoplasms 46Carcinoma, Renal Cell 43Carcinoma 39Stomach Neoplasms 36Prostatic Neoplasms 36Sarcoma 35Esophageal Neoplasms 35Uterine Cervical Neoplasms 34Squamous Cell Carcinoma of Head and Neck 34Adenocarcinoma 34Pleural Effusion, Malignant 33Recurrence 27Urinary Bladder Neoplasms 26

Interventions

90Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms, Male × Thoracic × Clear all
NCT00006370 2013-05-01

Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer

Novartis

Phase 2 Completed
275 enrolled
BreastThoracic

Breast Neoplasms, Lung Neoplasms, Breast Neoplasms, Male, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡